ResMed Inc., a leader in health technology focused on sleep and respiratory care, unveiled significant findings at SLEEP 2025, highlighting the cardiovascular benefits of CPAP therapy. Their research indicates that the use of CPAP therapy is associated with a 22% reduction in the risk of cardiovascular-related emergency room visits or hospitalizations. The studies also emphasize the positive impact of CPAP on obstructive sleep apnea symptoms and overall quality of life. Furthermore, ResMed is showcasing their expanded range of home-based testing solutions, which aim to simplify and expedite the diagnostic process for sleep disorders. The company's commitment to advancing sleep care is further underscored by their contribution to the American Academy of Sleep Medicine's 50th Anniversary Gallery, celebrating milestones in CPAP innovation.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。